2. Search Result
Search Result
Results for "

OXA-48

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139745
    FPI-1523 sodium

    		Beta-lactamase Bacterial Infection
    FPI-1523 sodium, a derivative of Avibactam, is a potent β-lactamase inhibitor, with Kds of 4 nM and 34 nM for CTX-M-15 and OXA-48, respectively. FPI-1523 sodium also inhibits PBP2, with an IC50 of 3.2 μM. FPI-1523 sodium exhibits considerable antimicrobial activity .
    FPI-1523 sodium
  • HY-109124A
    Taniborbactam hydrochloride
    5+ Cited Publications

    VNRX-5133 hydrochloride

    		 Beta-lactamase Bacterial Infection
    Taniborbactam hydrochloride (VNRX-5133 hydrochloride) is a reversible and selective boronic acid-containing pan-spectrum β-lactamase inhibitor with IC50s of 8-530 nM. Taniborbactam hydrochloride has IC50s of 30 nM, 32 nM, 42 nM, 20 nM for KPC-2, AmpC, OXA-48, and VIM-2. Taniborbactam hydrochloride is against Gram-negative bacteria .
    Taniborbactam hydrochloride
  • HY-125604
    WCK-4234

    		Beta-lactamase Bacterial Infection
    WCK-4234 is a potent β-lactamase inhibitor. WCK-4234 inhibits class A, C, and D β-lactamases activity. WCK-4234 lacks direct antibacterial activity. WCK-4234 potentiates imipenem and meropenem against Enterobacteriaceae with OXA-48/OXA-181 or KPC enzymes, or with combinations of impermeability and AmpC or ESBL activity. WCK-4234 distinctively overcomes resistance mediated by OXA-type carbapenemases .
    WCK-4234
  • HY-139745A
    FPI-1523

    		Beta-lactamase Bacterial Infection
    FPI-1523, a derivative of Avibactam, is a potent β-lactamase inhibitor, with Kds of 4 nM and 34 nM for CTX-M-15 and OXA-48, respectively. FPI-1523 also inhibits PBP2, with an IC50 of 3.2 μM. FPI-1523 exhibits considerable antimicrobial activity .
    FPI-1523
  • HY-139744
    FPI-1465

    		Beta-lactamase Penicillin-binding protein (PBP) Bacterial Infection
    FPI-1465 acts a dual inhibitor of serine-β-Lactamases and Penicillin-binding proteins (PBPs).FPI-1465 inhibits PBP2 (IC50=1.0 µg/mL). FPI-1465 exhibits activity against β-lactamase CTX-M-15 and OXA-48 with Kds of 0.011 and 5.3 µM, respectively .
    FPI-1465
  • HY-109124
    Taniborbactam

    VNRX-5133

    		 Beta-lactamase Bacterial Infection
    Taniborbactam (VNRX-5133) is a reversible and selective boronic acid-containing pan-spectrum β-lactamase inhibitor with IC50s of 8-530 nM. Taniborbactam has IC50s of 30 nM, 32 nM, 42 nM, 20 nM for KPC-2, AmpC, OXA-48, and VIM-2. Taniborbactam is against Gram-negative bacteria .
    Taniborbactam
  • HY-161094
    Metallo-β-lactamase-IN-12

    		Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-12 is a dual inhibitor of metal β-lactamases (MβLs (NDM-1, IMP-1)) and serine β-lactamases (SβLs (OXA-48, KPC-2)), with IC50 values of 0.64 μM, 1.32 μM, 1.01 μM, and 0.57 μM, respectively. Metallo-β-lactamase-IN-12 has antibacterial activity .
    Metallo-β-lactamase-IN-12
  • HY-111521
    Meropenem-vaborbactam

    Carbavance

    		 Others Infection
    Meropenem-vaborbactam is an antibiotic against nonfermenting Gram-negative clinical isolates, including Enterobacteriaceae isolates with resistant and carbapenemase genotypes. The susceptibility of Meropenem-vaborbactam (at an inhibitory concentration of 8 μg/ml) and comparators was tested against 14,304 nonfermenting Gram-negative clinical isolates collected worldwide in 2014 by reference broth microdilution. Carbapenemase-encoding genes were screened by PCR and sequencing. At concentrations of ≤1 and ≤2 μg/ml, Meropenem-vaborbactam inhibited 99.1 and 99.3% of the 10,426 Enterobacteriaceae isolates tested, respectively, while Meropenem inhibited 97.3 and 97.7% of these isolates at the same concentrations. For isolates displaying carbapenem-resistant Enterobacteriaceae (CRE) (n = 265), multiagent-resistant (MDR) (n = 1,210), and extensively agent-resistant (XDR) (n = 161) phenotypes, meropenem-vaborbactam had MIC50/90 values of 0.5/32, 0.03/1, and 0.5/32 μg/ml, respectively, while meropenem activity was 16/>32, 0.06/32, and 0.5/32 μg/ml, respectively. Among all geographic regions, activity was highest in the United States against CRE and MDR isolates (MIC50/90, 0.03/1 and 0.03/0.12 μg/ml, respectively). Meropenem-vaborbactam was highly active against 135 KPC-producing isolates, with all isolates inhibited at concentrations ≤8 μg/ml (133 isolates were inhibited at concentrations ≤2 μg/ml). The combination had limited activity against isolates producing metallo-β-lactamases (including 25 NDM-1 and 16 VIM producers) and/or oxocephalosporinases (27 OXA-48/OXA-163 producers), which were mainly found in the Asia-Pacific region and some European countries. Meropenem-vaborbactam had activity comparable to meropenem against Pseudomonas spp., Acinetobacter spp., and Clostridium amylovora. Meropenem-vaborbactam was active against a global collection of contemporary Enterobacteriaceae isolates, and the combination had greater activity against CRE isolates and KPC producers than did meropenem and most comparators, which are often multiagent-resistant.
    Meropenem-vaborbactam

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: